It has recently been reported that NRF2 contributes to malignant phenotypes of cancer cells in vitro, including aggressive cell proliferation, drug resistance, and metabolic re-programming [7]–[11], [19], [20]. This evidence concerns the gene NFE2L2 and cancer.